Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting.

Conti M, Pontiggia L, Vergani M, Muraca E, Cannistraci R, Perra S, Lattuada G, Perseghin G, Ciardullo S

Acta diabetologica16 Dec 2024Cited by 4 (Europe PMC)

PMID39680131DOI10.1007/s00592-024-02424-9PepBankPUB-39680131

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 6-month persistence to treatment was lower with oral semaglutide (85.3%) than with subcutaneous semaglutide (94.8%).
In plain wordsIn adults with type 2 diabetes, fewer people stayed on oral semaglutide than on injected semaglutide after 6 months.
Peptide
Semaglutide
Outcome
DecreaseTreatment persistence at 6 months
Study
n = 242
Comparator
Subcutaneous semaglutide
Analysis
Primary
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated · oral and subcutaneous · 6 monthsAs given in this study (human).
Measurements
Persistence at 6 months
85.3%
oral
Persistence at 6 months
94.8%
subcutaneous
Source sentences
Summary
The proportion of patients persistent to treatment was significantly lower in the oral group at 6 (85.3% vs. 94.8%; p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
This is a single-center, retrospective observational cohort study.
Summary · context
Patients with type 2 diabetes mellitus (T2DM) starting treatment with either formulation of semaglutide between January 1 2019 and July 31 2023 and with at least one follow-up visit were included.
Report a problemFND-3968013101
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12-month persistence to treatment was lower with oral semaglutide (72.3%) than with subcutaneous semaglutide (92.4%).
In plain wordsIn adults with type 2 diabetes, fewer people stayed on oral semaglutide than on injected semaglutide after 12 months.
Peptide
Semaglutide
Outcome
DecreaseTreatment persistence at 12 months
Study
n = 242
Comparator
Subcutaneous semaglutide
Analysis
Primary
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated · oral and subcutaneous · 12 monthsAs given in this study (human).
Measurements
Persistence at 12 months
72.3%
oral
Persistence at 12 months
92.4%
subcutaneous
Source sentences
Summary
The proportion of patients persistent to treatment was significantly lower in the oral group
3 context sentences(design, population, supporting numbers)
Summary · context
12 (72.3% vs. 92.4%, p < 0.001) and 18 (46.0% vs. 83.8%; p < 0.001) months.
Summary · context
This is a single-center, retrospective observational cohort study.
Summary · context
Patients with type 2 diabetes mellitus (T2DM) starting treatment with either formulation of semaglutide between January 1 2019 and July 31 2023 and with at least one follow-up visit were included.
Report a problemFND-3968013102
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 18-month persistence to treatment was lower with oral semaglutide (46.0%) than with subcutaneous semaglutide (83.8%).
In plain wordsIn adults with type 2 diabetes, fewer people stayed on oral semaglutide than on injected semaglutide after 18 months.
Peptide
Semaglutide
Outcome
DecreaseTreatment persistence at 18 months
Study
n = 242
Comparator
Subcutaneous semaglutide
Analysis
Primary
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated · oral and subcutaneous · 18 monthsAs given in this study (human).
Measurements
Persistence at 18 months
46%
oral
Persistence at 18 months
83.8%
subcutaneous
Source sentences
Summary
The proportion of patients persistent to treatment was significantly lower in the oral group
3 context sentences(design, population, supporting numbers)
Summary · context
18 (46.0% vs. 83.8%; p < 0.001) months.
Summary · context
This is a single-center, retrospective observational cohort study.
Summary · context
Patients with type 2 diabetes mellitus (T2DM) starting treatment with either formulation of semaglutide between January 1 2019 and July 31 2023 and with at least one follow-up visit were included.
Report a problemFND-3968013103
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, after adjustment for age and BMI, body weight reduction did not differ significantly between oral and subcutaneous semaglutide.
In plain wordsIn adults with type 2 diabetes, weight loss was not significantly different between oral and injected semaglutide.
Peptide
Semaglutide
Outcome
No significant changeBody weight reduction, oral versus subcutaneous
Study
n = 242
Comparator
Subcutaneous semaglutide
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oral and subcutaneousAs given in this study (human).
Source sentences
Summary
When adjusted for age and BMI, body weight and HbA1c reduction were not significantly different between the two formulations, as the proportion of patients achieving the composite outcome of weight loss ≥ 5% and HbA1c < 7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a single-center, retrospective observational cohort study.
Summary · context
Patients with type 2 diabetes mellitus (T2DM) starting treatment with either formulation of semaglutide between January 1 2019 and July 31 2023 and with at least one follow-up visit were included.
Report a problemFND-3968013105
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, after adjustment for age and BMI, HbA1c reduction did not differ significantly between oral and subcutaneous semaglutide.
In plain wordsIn adults with type 2 diabetes, HbA1c reduction was not significantly different between oral and injected semaglutide.
Peptide
Semaglutide
Outcome
No significant changeHbA1c reduction, oral versus subcutaneous
Study
n = 242
Comparator
Subcutaneous semaglutide
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral and subcutaneousAs given in this study (human).
Source sentences
Summary
When adjusted for age and BMI, body weight and HbA1c reduction were not significantly different between the two formulations, as the proportion of patients achieving the composite outcome of weight loss ≥ 5% and HbA1c < 7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a single-center, retrospective observational cohort study.
Summary · context
Patients with type 2 diabetes mellitus (T2DM) starting treatment with either formulation of semaglutide between January 1 2019 and July 31 2023 and with at least one follow-up visit were included.
Report a problemFND-3968013106
06HumanObservational studySafety outcome
In adults with type 2 diabetes who stopped semaglutide, the most common reasons for discontinuation were gastrointestinal side effects.
In plain wordsIn adults with type 2 diabetes who stopped semaglutide, stomach and gut side effects were the most common reason.
Peptide
Semaglutide
Outcome
Not applicableReasons for discontinuation
Study
n = 242
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · oral and subcutaneousAs given in this study (human).
Source sentences
Summary
Most common reasons for discontinuation were gastro-intestinal side effects.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a single-center, retrospective observational cohort study.
Summary · context
Patients with type 2 diabetes mellitus (T2DM) starting treatment with either formulation of semaglutide between January 1 2019 and July 31 2023 and with at least one follow-up visit were included.
Report a problemFND-3968013104
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, after adjustment for age and BMI, the proportion reaching the composite of weight loss of 5% or more and HbA1c below 7.0% did not differ significantly between oral and subcutaneous semaglutide.
In plain wordsIn adults with type 2 diabetes, reaching both a 5% weight loss and HbA1c below 7.0% did not differ significantly between oral and injected semaglutide.
Peptide
Semaglutide
Outcome
No significant changeComposite of weight loss of 5% or more and HbA1c below 7.0%
Study
n = 242
Comparator
Subcutaneous semaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral and subcutaneousAs given in this study (human).
Source sentences
Summary
When adjusted for age and BMI, body weight and HbA1c reduction were not significantly different between the two formulations, as the proportion of patients achieving the composite outcome of weight loss ≥ 5% and HbA1c < 7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a single-center, retrospective observational cohort study.
Summary · context
Patients with type 2 diabetes mellitus (T2DM) starting treatment with either formulation of semaglutide between January 1 2019 and July 31 2023 and with at least one follow-up visit were included.
Report a problemFND-3968013107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords